Impact of microbiota on breast cancer hormone therapy
Authors:Safae Terrisse1, Laurence Zitvogel2-5 and Guido Kroemer6-8
1 Medical Oncology, Hôpital Saint-Louis, Paris, France.
2 INSERM U1015, Equipe Labellisée – Ligue Nationale contre le Cancer, Villejuif, France.
3 University Paris Saclay, Gif-sur-Yvette, France.
4 Gustave Roussy, ClinicObiome, Villejuif, France.
5 Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
6 Equipe labellisée par la Ligue contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Inserm U1138, Centre de Recherche des Cordeliers, Paris, France.
7 Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
8 Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
Keywords:
breast cancer, hormone therapy, microbiota, immunity.
Abbreviations:
ADT – androgen deprivation therapy;
BC – breast cancer;
CTL – cytotoxic T lymphocyte;
DMBA – 7,12-dimethylbenz[a]anthracene;
HR+ – hormone-receptor positive;
MPA – medroxyprogesterone acetate;
TIL – tumor-infiltrating lymphocyte;
TNBC – triple negative BR;
Treg – regulatory T cell.
Corresponding Author(s):
Conflict of interest statement:
GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys, and Vascage. GK has been consulting for Reithera. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Thera-peutics and Therafast Bio. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. GK’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. LZ has held research con-tracts with 9 Meters Biopharma, Daiichi Sankyo, Pileje, was on the on the Board of Directors of Transgene. LZ is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipula-tion of the microbiota (in particular using Akkermansia species).
Please cite this article as:
Safae Terrisse, Laurence Zitvogel and Guido Kroemer (2023). Impact of microbiota on breast cancer hormone therapy. Cell Stress 7(3): 12-19. doi: 10.15698/cst2023.03.277
© 2023 Terrisse et al. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.
Abstract:
Recent observations indicate that the pathogenesis and prognosis of hormone-receptor breast cancer is not only dictated by the properties of the malignant cells but also by immune and microbial parameters. Thus, the immunosurveillance system retards the development of hormone-positive breast cancer and contributes to the therapeutic efficacy of estrogen receptor antagonists and aromatase inhibitors. Moreover, the anticancer immune response is profoundly modulated by the local and intestinal microbiota, which influences cancer cell-intrinsic signaling pathways, affects the composition and function of the immune infiltrate present in the tumor microenvironment and modulates the metabolism of estrogens. Indeed, specific bacteria in the gut produce enzymes that affect the enterohepatic cycle of estrogen metabolites, convert estrogens into androgens or generate estrogen-like molecules. The knowledge of these circuitries is in its infancy, calling for further in-depth analyses.